News

45% of study participants were either dissatisfied or very dissatisfied with their current medical treatment.

The pivotal DERMIS trial author discusses extended assessment and prescribing strategies for the latest psoriasis agent.

A retrospective analysis suggests there are significant disparities in dermatologist visit duration based on patient race and ethnicity.

Dermatologist Raj Chovatiya, MD, PhD, discusses practical use of the newest topical therapy approved by the FDA.

Dr. Levine talks with Dr. Lisa Harding about how clinicians can best improve patient care in psychiatry.

A larger circadian photoreceptor responsivity was significantly linked to a later dim-light melatonin onset in light drinkers.

Mean age of hypertension diagnosis was 4 - 5 years earlier among Black and Hispanic adults vs White adults between 2011 and 2020.

President and CSO of Odylia Therapeutics discusses the gene therapy pipeline, research and differences in operating as a nonprofit biotech company.

The biosimilar product was deemed interchangeable with ranibizumab injection across all five retinal indications.

The Cleveland Clinic Director of Sleep Disorders Research navigates the complexities of OSA presentation, progression, management and eradication with the Lungcast team.

Study data show 14% of eyes managed with intravitreal therapy in routine clinical care experienced ≥ 10 letter loss.

Investigators believe these results could help improve disease recognition and diagnosis while supporting development of personalized prevention and therapy.

Dr. David Hudesman expects drug developers to continue to target biologics for the treatment of IBD.

Repeated metabolite monitoring with subsequent dose optimization resulted in 67.2% of patients achieving therapeutic levels after 1 year and 87.8% of patients achieving steroid-free remission, while 90% had no therapy escalation or surgery.

Prior to the launch of FSR's webinar on pulmonary sarcoidosis, Mary McGowan, CEO, discusses the private listening session held with the FDA that addressed the critical needs in the field.

Dapagliflozin consistently reduced the risk of CV death or HHF, HHF alone, and progression of kidney disease regardless of background use of CV medications, investigators say.

Patients treated with LAIAs had a lower risk of hospitalization for any cause, hospitalizations for psychiatric disorders, hospitalizations for schizophrenia, and incident suicide attempts compared to patients treated with oral antipsychotics.

Cross-sectional data suggest a discontinuity in endothelial cell–density measurements just below 2500 cells.

The age-adjusted mortality rates for heart failure in young adults increased from 2.36 in 1999 to 3.16 in 2019.

Symptom flare-ups in patients on a gluten-free diet were significantly lower than in patients on a high-gluten diet.

The prevalence of suicidal was 10.9% in studies that included child-reported outcomes for child only and 10.4% for child and parent combined.

At the 2022 ASPC annual meeting, Dr. Gluckman highlights the overall impact of the economic cost of cardiovascular disease and the role of prevention.

Dr. Kushner discusses obesity as a risk factor for CVD and how preventive cardiologists can better target weight management to support patient health.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

The highest adjusted probability of CGM use occurred in middle adulthood, while the probability of CGM utilization decreased with increasing age in older adulthood.

After March 2020, overdose deaths not involving methadone continued to increase whereas methadone-involved overdose deaths remained stable.

The association with depressive symptoms was greater when race, ancestry, or national origins among Hispanic or Latino participants was the main reason for discrimination.

An analysis of survey responses show tolerance toward public health official harassment and threatening has worsened since 2020.